Form 4: Yubo Biotech CEO Converts Debt to Equity, Acquiring 8.6 Million Shares

Yubo International Biotech Ltd's CEO, Wang Yang, acquired 8.6 million Class A Common Stock shares at $0.05 each by converting $430,000 of company debt into equity.

Summary

• Wang Yang, who serves as Chief Executive Officer, Director, and a 10% Owner of Yubo International Biotech Ltd (YBGJ), acquired 8,600,000 shares of Class A Common Stock.
• The transaction occurred on July 23, 2025, with shares priced at $0.05 each.
• The total value of the shares acquired amounts to $430,000.
• The acquisition was executed pursuant to a Securities Purchase Agreement dated July 23, 2025.
• The consideration for these shares was the cancellation of certain indebtedness owed by Yubo International Biotech Ltd to Wang Yang.
• Following this transaction, Wang Yang beneficially owns 25,811,400 shares indirectly through Chinaone Technology Limited, an entity in which he holds a 100% equity interest.

Sentiment

Score: 6

Explanation: The conversion of debt to equity by the CEO is a positive step for the company's balance sheet health, reducing liabilities and demonstrating insider confidence. However, the low share price of the transaction and the resulting dilution for existing shareholders temper the overall positive sentiment.

Positives

• Debt reduction: The company's indebtedness is reduced by $430,000 through the conversion of debt into equity.
• Strengthened balance sheet: Converting debt to equity improves the company's debt-to-equity ratio and overall financial health by reducing liabilities.
• Management commitment: The CEO's willingness to convert debt into equity demonstrates confidence in the company's future and further aligns his interests with those of shareholders.

Negatives

• Share dilution: The issuance of 8,600,000 new shares dilutes the ownership percentage of existing shareholders.
• Low share price: The transaction occurred at a price of $0.05 per share, which is a very low valuation, potentially indicating underlying financial challenges or a low market capitalization.

Future Outlook

No forward-looking statements or guidance regarding future performance or strategic direction are provided.

Industry Context

This transaction represents a common corporate finance strategy where a company converts debt owed to an insider into equity. This maneuver is often employed to improve the company's balance sheet, reduce interest expenses, and conserve cash, particularly in companies that may be in a growth phase or facing liquidity challenges. It suggests a focus on strengthening the capital structure.

Comparison to Industry Standards

• Debt-to-equity conversions by insiders are a recognized mechanism for recapitalization, frequently observed in smaller, growth-oriented, or financially constrained companies across various sectors, including biotechnology. This allows companies to reduce liabilities without incurring cash outflows.
• While the specific terms (e.g., $0.05 per share) are unique to this transaction, the strategic intent of improving the balance sheet through insider debt conversion aligns with practices seen in companies seeking to optimize their capital structure or avoid traditional financing at potentially unfavorable terms.

Related Party Transactions

• The transaction involves Wang Yang, who is the Chief Executive Officer, a Director, and a 10% Owner of Yubo International Biotech Ltd.
• Wang Yang acquired shares from the Issuer by converting indebtedness owed to him by the Issuer.
• The shares were acquired through Chinaone Technology Limited, an entity that is 100% owned by Wang Yang, making it an indirect acquisition by a related party.

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of new shares, but benefit from a strengthened company balance sheet and reduced debt, which can improve long-term financial stability.
• Creditors: Benefit from a stronger balance sheet and reduced overall debt, potentially improving the company's creditworthiness and ability to meet future obligations.
• Management/Insiders: Wang Yang's ownership stake increases, further aligning his financial interests with the company's long-term success and demonstrating a commitment to its future.

Key Dates

Recommendation

While the debt-to-equity conversion is a positive for the company's balance sheet and signals insider confidence, the very low transaction price of $0.05 per share and the resulting dilution warrant caution. Investors should hold to observe the company's future financial performance and strategic direction following this recapitalization, as the low price suggests underlying challenges that need to be addressed for sustained growth.

Keywords

Yubo International Biotech, YBGJ, SEC Form 4, insider transaction, debt conversion, equity issuance, CEO, beneficial ownership, share acquisition, related party transaction, corporate finance, balance sheet restructuring